Decreased Amyloid-β and Increased Neuronal Hyperactivity by Immunotherapy in Alzheimer's Models

Overview

Journal Nat Neurosci

Date 2015 Nov 10

PMID 26551546

Citations 66

Authors

Marc Aurel Busche

Christine Grienberger

Aylin D Keskin

Beomjong Song

Ulf Neumann

Matthias Staufenbiel

Hans Forstl

Arthur Konnerth

Affiliations

Soon will be listed here.

Abstract

Among the most promising approaches for treating Alzheimer's disease is immunotherapy with amyloid-β (Aβ)-targeting antibodies. Using in vivo two-photon imaging in mouse models, we found that two different antibodies to Aβ used for treatment were ineffective at repairing neuronal dysfunction and caused an increase in cortical hyperactivity. This unexpected finding provides a possible cellular explanation for the lack of cognitive improvement by immunotherapy in human studies.

Citing Articles

Can brain network connectivity facilitate the clinical development of disease-modifying anti-Alzheimer drugs?.

Pini L, Lista S, Griffa A, Allali G, Imbimbo B Brain Commun. 2025; 7(1):fcae460.

PMID: 39741782 PMC: 11686405. DOI: 10.1093/braincomms/fcae460.

Cannabidiol ameliorates cognitive decline in 5×FAD mouse model of Alzheimer's disease through potentiating the function of extrasynaptic glycine receptors.

Jin J, Fu C, Xia J, Luo H, Wang X, Chen S Mol Psychiatry. 2024; .

PMID: 39396064 DOI: 10.1038/s41380-024-02789-x.

Neuronal hypofunction and network dysfunction in a mouse model at an early stage of tauopathy.

Ji C, Yang X, Eleish M, Jiang Y, Tetlow A, Song S Alzheimers Dement. 2024; 20(11):7954-7970.

PMID: 39368113 PMC: 11567809. DOI: 10.1002/alz.14273.

Amyloid-β in Alzheimer's disease: Structure, toxicity, distribution, treatment, and prospects.

Yu Y, Yu S, Battaglia G, Tian X Ibrain. 2024; 10(3):266-289.

PMID: 39346788 PMC: 11427815. DOI: 10.1002/ibra.12155.

Early hippocampal hyperexcitability and synaptic reorganization in mouse models of amyloidosis.

Ray A, Loghinov I, Ravindranath V, Barth A iScience. 2024; 27(9):110629.

PMID: 39262788 PMC: 11388185. DOI: 10.1016/j.isci.2024.110629.

References

Grienberger C, Rochefort N, Adelsberger H, Henning H, Hill D, Reichwald J . Staged decline of neuronal function in vivo in an animal model of Alzheimer's disease. Nat Commun. 2012; 3:774. PMC: 3337977. DOI: 10.1038/ncomms1783. View

Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C . Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature. 1995; 373(6514):523-7. DOI: 10.1038/373523a0. View

Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S . Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 1996; 274(5284):99-102. DOI: 10.1126/science.274.5284.99. View

Palop J, Chin J, Roberson E, Wang J, Thwin M, Bien-Ly N . Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron. 2007; 55(5):697-711. PMC: 8055171. DOI: 10.1016/j.neuron.2007.07.025. View

Lee M, Motter R, Hu K, Gordon G, Barbour R, Khan K . Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease. Proc Natl Acad Sci U S A. 1997; 94(4):1550-5. PMC: 19829. DOI: 10.1073/pnas.94.4.1550. View

Vossel K, Beagle A, Rabinovici G, Shu H, Lee S, Naasan G . Seizures and epileptiform activity in the early stages of Alzheimer disease. JAMA Neurol. 2013; 70(9):1158-66. PMC: 4013391. DOI: 10.1001/jamaneurol.2013.136. View

Pfeifer M, Boncristiano S, Bondolfi L, Stalder A, Deller T, Staufenbiel M . Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science. 2002; 298(5597):1379. DOI: 10.1126/science.1078259. View

Sperling R, Mormino E, Johnson K . The evolution of preclinical Alzheimer's disease: implications for prevention trials. Neuron. 2014; 84(3):608-22. PMC: 4285623. DOI: 10.1016/j.neuron.2014.10.038. View

Bard F, Barbour R, Cannon C, Carretto R, Fox M, Games D . Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci U S A. 2003; 100(4):2023-8. PMC: 149952. DOI: 10.1073/pnas.0436286100. View

10.

Karran E, Mercken M, De Strooper B . The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov. 2011; 10(9):698-712. DOI: 10.1038/nrd3505. View

11.

Schroeter S, Khan K, Barbour R, Doan M, Chen M, Guido T . Immunotherapy reduces vascular amyloid-beta in PDAPP mice. J Neurosci. 2008; 28(27):6787-93. PMC: 6670967. DOI: 10.1523/JNEUROSCI.2377-07.2008. View

12.

Bard F, Cannon C, Barbour R, Burke R, Games D, Grajeda H . Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000; 6(8):916-9. DOI: 10.1038/78682. View

13.

Green K, Billings L, Roozendaal B, McGaugh J, LaFerla F . Glucocorticoids increase amyloid-beta and tau pathology in a mouse model of Alzheimer's disease. J Neurosci. 2006; 26(35):9047-56. PMC: 6675335. DOI: 10.1523/JNEUROSCI.2797-06.2006. View

14.

Garaschuk O, Milos R, Konnerth A . Targeted bulk-loading of fluorescent indicators for two-photon brain imaging in vivo. Nat Protoc. 2007; 1(1):380-6. DOI: 10.1038/nprot.2006.58. View

15.

Nimmerjahn A, Kirchhoff F, Helmchen F . Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science. 2005; 308(5726):1314-8. DOI: 10.1126/science.1110647. View

16.

Stosiek C, Garaschuk O, Holthoff K, Konnerth A . In vivo two-photon calcium imaging of neuronal networks. Proc Natl Acad Sci U S A. 2003; 100(12):7319-24. PMC: 165873. DOI: 10.1073/pnas.1232232100. View

17.

Wilcock D, Munireddy S, Rosenthal A, Ugen K, Gordon M, Morgan D . Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration. Neurobiol Dis. 2004; 15(1):11-20. DOI: 10.1016/j.nbd.2003.09.015. View

18.

Buttini M, Masliah E, Barbour R, Grajeda H, Motter R, Johnson-Wood K . Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease. J Neurosci. 2005; 25(40):9096-101. PMC: 6725749. DOI: 10.1523/JNEUROSCI.1697-05.2005. View

19.

Spires-Jones T, Mielke M, Rozkalne A, Meyer-Luehmann M, de Calignon A, Bacskai B . Passive immunotherapy rapidly increases structural plasticity in a mouse model of Alzheimer disease. Neurobiol Dis. 2008; 33(2):213-20. PMC: 2672591. DOI: 10.1016/j.nbd.2008.10.011. View

20.

Busche M, Eichhoff G, Adelsberger H, Abramowski D, Wiederhold K, Haass C . Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer's disease. Science. 2008; 321(5896):1686-9. DOI: 10.1126/science.1162844. View